Nuvilex investors need to realize the importance of the Von Hoff TD2 study...unlike the 2b study being readied for the first part of next year that when completed Nuvilex plans on filing for approval for Cell_in_a_Box for Pancreatic Cancer...Nuvilex's TD2 study being a preclinical mouse study it would be easy to think that the results of this study is not going to benefit Nuvilex in the near future...that any value will not be seen for years... nothing could be more untrue...
In the last PR "The current standard of care requires that malignant ascites fluid be removed from the abdomen of cancer patients " if you have never seen anyone with ascites google (pics of ascites)...the unbearable pain these poor patients must go through is hard to look at especially the ones of the babies...the process of removing the ascites fluid must be very painful too...you can also see pics of that...they do not remove it with a needle...they cut the patient open and suck out the fluid...as Von Hoff has said the pain usually kills these patients before the cancer does...the study even if it only slows the onset of ascites means these patients will have this process does less often...
We also learned several things from the last PR that was a surprise to all of us...that the mice would be injected with human ovarian cancer cells because(i) they reproduce rapidly and form tumors; and (ii) the resultant tumors are proficient at producing malignant ascites fluid...
And we learned that there would be 4 groups in the study...
One group of mice will be treated with Nuvilex's pancreatic cancer treatment consisting of the combination of Cell-in-a-Box(R) encapsulated live cells and the cancer prodrug ifosfamide (the encapsulated cells express an enzyme, CYP2B1, which converts ifosfamide into its cancer-killing form)...
A second group of mice will be treated with a drug normally used to treat ovarian cancer...
A third group will be administered that drug along with Nuvilex's Cell-in-a-Box(R) encapsulated live cells and ifosfamide combination...
The remaining mice will serve as the "control" group for comparison purposes...
so not only do we get to see what our original therapy can do for ascites...but we also get to see what CiaB can do with combo drugs...
why is this important...first to see CiaB with a different cancer drug...and to see how the cancer community responds to that...
so there is no doubt in my mind that other bio companies have a close eye on this study especially with Von Hoff at the helm of it...I can think of one in particular that has a lot to lose if our trials take us to approval but I can also see that our CiaB could not only benefit that company but others...with other drugs and other diseases...
We are being watched and this little preclinical study is the one with the magnifying glass on top of it...
bull
News 
Market Data 
Discover 
